BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, July 29, 2026
Home » Topics » Briefs » Regulatory actions

Regulatory actions
Regulatory actions RSS Feed RSS

Regulatory actions for Feb. 6, 2026

Feb. 6, 2026
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Biocomposites, Eyas, Insightec, Mirum, Sonorous Neurovascular.
Read More

Regulatory actions for Feb. 5, 2026

Feb. 5, 2026
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Acarix, Balt, Cumberland, Hologic, Ingeneron, Oncolytics, TSC.
Read More

Regulatory actions for Feb. 4, 2026

Feb. 4, 2026
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Abbvie, Acadia, Astrazeneca, Daiichi Sankyo, Medtronic, Promega, Quanterix, Relay, Revealdx, Zeiss.
Read More

Regulatory actions for Feb. 3, 2026

Feb. 3, 2026
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Aquestive, ARS, Astrazeneca, Cynosure Lutronic, Elevar, Exelixis, Galderma, GE, Incyte, Moonlake, Natera, OS Therapies, Pharming, Tuhura.
Read More

Regulatory actions for Feb. 3, 2026

Feb. 3, 2026
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations in Asia-Pacific: Almirall, Bioarctic, Biogen, Drug Farm, Eisai, Huahui, Otsuka, Quoin.
Read More

Regulatory actions for Feb. 2, 2026

Feb. 2, 2026
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Chiesi, Eli Lilly, Johnson & Johnson, Protalix, Sanofi, Ultragenyx, Unicycive.
Read More

Regulatory actions for Jan. 30, 2026

Jan. 30, 2026
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Almirall, Elevar, Summit, Tenpoint.
Read More

Regulatory actions for Jan. 30, 2026

Jan. 30, 2026
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Koru Medical, Siemens Healthineers.
Read More

Regulatory actions for Jan. 29, 2026

Jan. 29, 2026
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Biogen, Drug Farm, Glaukos, Guerbet, Immix , Johnson & Johnson, Shorla.
Read More

Regulatory actions for Jan. 29, 2026

Jan. 29, 2026
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: CSD Labs, Nextbiomedical, Spectrum Dynamics.
Read More
Previous 1 2 … 11 12 13 14 15 16 17 18 19 … 343 344 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 28, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 28, 2026
  • Illustration of dopamine signaling in the brain

    New schizophrenia targets challenge trial design

    BioWorld
    The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
  • EMA logo on mobile screen, vials, syringes

    Daybu readthrough in EU? Zevra’s NPC bid flounders

    BioWorld
    Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
  • Regulatory actions for July 27, 2026

    BioWorld
    Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing